Atlas of Endometrial Histopathology

Dallenbach-Hellweg, Gisela; Schmidt, Dietmar; Dallenbach, Friederike

doi:10.1007/978-3-642-01541-0

Cited by 15 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…DNG, which may be used for 1 year or more [1314], was used instead of a GnRH-a which has a limited duration of use, as it decreases bone mineral density. A comparative trial of DNG (2 mg/day) versus a GnRH-a [1516] concluded that DNG is as effective for the relief of pain associated with endometriosis [15].…”

Section: Discussionmentioning

confidence: 99%

“…No serious adverse events were observed. Data from long-term studies indicated that pain relief continued to improve with sustained DNG therapy for 1 year and beyond [1420]. DNG can also induce decidualization of ectopic endometrial tissue and atrophy of lesions with continued treatment by creating a hypoestrogenic and hyperprogestogenic endocrine environment; thus, DNG is effective in treating endometriosis at a dose of 2 mg daily [6].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis

Kim

et al. 2016

Obstet Gynecol Sci

View full text Add to dashboard Cite

ObjectiveTo evaluate the effect of orally administered dienogest (DNG) for dysmenorrhea and pelvic pain associated with endometriosis.MethodsFor this study we recruited 89 patients with dysmenorrhea and pelvic pain associated with endometriosis diagnosed by laparoscopy. All patients complained of persistent dysmenorrhea and pelvic pain despite surgical treatment 6 months previously. After 6 months of DNG treatment, we used a 0 to 3 point verbal rating scale to measure the severity of disability in daily life due to dysmenorrhea and pelvic pain, and the use of analgesics. Weight gain, serum lipid and liver enzyme tests were performed before treatment and after 6 months of DNG treatment.ResultsTotal dysmenorrhea scores assessed by the verbal rating scale significantly decreased by the end of treatment (P<0.001). The mean (±standard deviation) pain score for dysmenorrhea before and after treatment were 1.42±1.1 and 0.1±0.3, respectively. The mean non-menstrual pelvic pain scores before and after treatment were 0.52±0.6 and 0.18±0.3, respectively, showing a significant difference (P<0.001). The use of analgesics significantly decreased by the end of the treatment (P<0.001). The associated adverse effects were weight gains (in 56 of 89 patients, 63%) and uterine bleeding (in 28 of 89 patients, 31.5%). The weight gain (before treatment, 57.9±9.7; after treatment, 61.1±12.6) was statistically significant (P<0.040).ConclusionThis study demonstrated that orally administered DNG could be used to effectively treat dysmenorrhea and pelvic pain associated with endometriosis although the side effects of weight gain and uterine bleeding should be considered.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis

Kim

et al. 2016

Obstet Gynecol Sci

View full text Add to dashboard Cite

show abstract

“…Occasionally, endometrial biopsy demonstrates more subtle and less well‐defined alterations, including deficiencies in endometrial secretory maturation as compared with that expected for the cycle date or apparent hormonal milieu. These include changes attributed to an inadequate secretory phase, also known as luteal‐phase insufficiency or luteal‐phase defect (LPD), where there may be a uniform delay in maturation affecting both epithelial and stromal elements, or a more localized alteration typically affecting only the endometrial glands . The latter is characterized by an admixture of secretory and non‐secretory epithelial changes, which have been variably called irregular endometrial ripening or maturation, mixed secretory pattern endometrium, and dysynchronous or asynchronous endometrial glands (AEGs) .…”

Section: Introductionmentioning

confidence: 99%

“…Although sometimes included within the spectrum of LPD, as noted above, the localized nature of the change is more suggestive of a primary endometrial abnormality than a central endocrinological deficiency or corpus luteum defect. Indeed, it has been suggested that AEGs may result from a clonal alteration in the endometrial epithelium . Recently, Russell et al .…”

Section: Introductionmentioning

confidence: 99%

“…These include changes attributed to an inadequate secretory phase, also known as lutealphase insufficiency or luteal-phase defect (LPD), where there may be a uniform delay in maturation affecting both epithelial and stromal elements, or a more localized alteration typically affecting only the endometrial glands. [1][2][3][4][5] The latter is characterized by an admixture of secretory and non-secretory epithelial changes, which have been variably called irregular endometrial ripening or maturation, mixed secretory pattern endometrium, and dysynchronous or asynchronous endometrial glands (AEGs). [3][4][5][6][7][8] Overlapping morphological changes may also be seen in 'irregular endometrial shedding', which is postulated to result from abnormal persistence of the corpus luteum, [4][5][6]9 or to the oestrogenic effects of a persistent Graafian follicle.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Asynchronous glands in secretory pattern endometrium: clinical associations and immunohistological changes

2015

View full text Add to dashboard Cite

show abstract

The effectiveness of using a molded sorbent: Modified polyvinylpyrrolidone for the combined treatment of chronic endometritis

Баринов

Tirskaya

Borisova

et al. 2021

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Objective To improve the management of patients with chronic endometritis (CE) by using a molded sorbent—modified by polyvinylpyrrolidone (FSMP). Methods This prospective study included 70 patients with CE divided into two groups: group 1 (n = 23) received traditional antibiotic therapy (from days 3 to 10 of the menstrual cycle); group 2 (n = 47), received antibiotics and FSMP was inserted from days 5 to 10. Results At the end of therapy, group 1 had massive growth of pathogenic microflora in 21.7%, moderate growth in 69.6%, and no growth in 8.7% of cases. In group 2, after combined therapy, massive growth was observed in 4.3%, moderate growth in 44.7%, and no growth in 51.0%. In group 2 after 5 days, serum levels of interleukin‐1β (IL‐1β) were 1.9 times, of IL‐6 were 7.0 times, and of IL‐8 and IL‐1 receptor antagonist were 1.3 times lower than in group 1. In uterine cavity aspirates, IL‐1β decreased around 4.8 times, IL‐6 by 11.8 times, IL‐8 by 3.2 times, tumor necrosis factor‐α by 3.9 times, and IL‐1 receptor antagonist by 2.1 times in comparison to group 1. Conclusion Combined therapy of FSMP with antibiotics is more effective in treating CE, because it contributes to the almost complete elimination of pathogens and toxins from the uterine cavity, blocking the local pro‐inflammatory cascade.

show abstract

Atlas of Endometrial Histopathology

Cited by 15 publications

References 0 publications

Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis

Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis

Asynchronous glands in secretory pattern endometrium: clinical associations and immunohistological changes

The effectiveness of using a molded sorbent: Modified polyvinylpyrrolidone for the combined treatment of chronic endometritis

Contact Info

Product

Resources

About